Literature DB >> 20431551

Clinical guidelines: Unraveling the tautology of polymyalgia rheumatica.

Eric L Matteson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20431551     DOI： 10.1038/nrrheum.2010.40

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  5 in total

1.  Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey.

Authors:  Bhaskar Dasgupta; Carlo Salvarani; Michael Schirmer; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

2.  BSR and BHPR guidelines for the management of polymyalgia rheumatica.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2009-11-12       Impact factor: 7.580

3.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

4.  The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.

Authors:  M A González-Gay; C García-Porrúa; M Vázquez-Caruncho; A Dababneh; A Hajeer; W E Ollier
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

Review 5.  Treatment of polymyalgia rheumatica: a systematic review.

Authors:  José Hernández-Rodríguez; Maria C Cid; Alfons López-Soto; Georgina Espigol-Frigolé; Xavier Bosch
Journal:  Arch Intern Med       Date:  2009-11-09
  5 in total
  4 in total

Review 1.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

2.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

3.  Optimal management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Rodger Charlton
Journal:  Ther Clin Risk Manag       Date:  2012-04-05       Impact factor: 2.423

4.  Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.

Authors:  Arthur E Brawer
Journal:  Open Access Rheumatol       Date:  2016-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.